GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia

J. Cortes, H. Kantarjian, S. O'Brien, R. Kurzrock, M. Keating, M. Talpaz

Research output: Contribution to journalArticle

Abstract

Patients with chronic myelogenous leukemia (CML) who achieve a major cytogenetic remission when treated with interferon-α (IFN-A) have a survival advantage when compared to patients with no cytogenetic response. We investigated the effect of combining granulocyte-macrophage colony-stimulating factor (GM-CSF) with IFN-A in the cytogenetic response of patients with minor responses to IFN-A alone. CML patients were eligible if they had shown sensitivity to IFN-A as determined by achievement of a hematologic or cytogenetic response, but failed to achieve or lost a major cytogenetic response after a minimum of 12 months of therapy with IFN-A alone. Patients received GM-CSF 30 μg/m2 daily, subcutaneously and the dose was escalated to 60 μg/m2 if tolerated. IFN-A was continued at the same dose being received by the patient and escalated when possible. Fourteen evaluable patients were included, 13 in chronic phase and one in accelerated phase. The best response prior to GM-CSF was a transient major cytogenetic response in two patients (14%), minor cytogenetic response in nine (64%), and complete hematologic response in three (22%). The median time on IFN-A prior to the start of GM-CSF was 39 months (range 12-72 months). Four patients achieved a significant cytogenetic response, including two complete (14%) and two partial (14%) cytogenetic remissions during therapy. One partial cytogenetic remission converted to complete shortly after therapy was discontinued. Two other patients had a significant reduction in the percentage of Philadelphia chromosome-positive metaphases. The dose of IFN-A could be escalated in half of the patients treated. No toxicity could be attributed to the addition of GM-CSF. We conclude that the addition of GM-CSF to the treatment with IFN-A in CML patients who are sensitive to IFN-A alone but fail to achieve a major cytogenetic response may be beneficial in some patients and should be further investigated.

Original languageEnglish (US)
Pages (from-to)860-864
Number of pages5
JournalLeukemia
Volume12
Issue number6
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferon-alpha
Cytogenetics
Therapeutics
Philadelphia Chromosome
Metaphase
Interferons

Keywords

  • Chronic myelogenous leukemia
  • Cytogenetic response
  • GM-CSF
  • Interferon-alfa

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. / Cortes, J.; Kantarjian, H.; O'Brien, S.; Kurzrock, R.; Keating, M.; Talpaz, M.

In: Leukemia, Vol. 12, No. 6, 01.01.1998, p. 860-864.

Research output: Contribution to journalArticle

Cortes, J. ; Kantarjian, H. ; O'Brien, S. ; Kurzrock, R. ; Keating, M. ; Talpaz, M. / GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. In: Leukemia. 1998 ; Vol. 12, No. 6. pp. 860-864.
@article{8c5119ff24ad4ff29332035777599aa7,
title = "GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia",
abstract = "Patients with chronic myelogenous leukemia (CML) who achieve a major cytogenetic remission when treated with interferon-α (IFN-A) have a survival advantage when compared to patients with no cytogenetic response. We investigated the effect of combining granulocyte-macrophage colony-stimulating factor (GM-CSF) with IFN-A in the cytogenetic response of patients with minor responses to IFN-A alone. CML patients were eligible if they had shown sensitivity to IFN-A as determined by achievement of a hematologic or cytogenetic response, but failed to achieve or lost a major cytogenetic response after a minimum of 12 months of therapy with IFN-A alone. Patients received GM-CSF 30 μg/m2 daily, subcutaneously and the dose was escalated to 60 μg/m2 if tolerated. IFN-A was continued at the same dose being received by the patient and escalated when possible. Fourteen evaluable patients were included, 13 in chronic phase and one in accelerated phase. The best response prior to GM-CSF was a transient major cytogenetic response in two patients (14{\%}), minor cytogenetic response in nine (64{\%}), and complete hematologic response in three (22{\%}). The median time on IFN-A prior to the start of GM-CSF was 39 months (range 12-72 months). Four patients achieved a significant cytogenetic response, including two complete (14{\%}) and two partial (14{\%}) cytogenetic remissions during therapy. One partial cytogenetic remission converted to complete shortly after therapy was discontinued. Two other patients had a significant reduction in the percentage of Philadelphia chromosome-positive metaphases. The dose of IFN-A could be escalated in half of the patients treated. No toxicity could be attributed to the addition of GM-CSF. We conclude that the addition of GM-CSF to the treatment with IFN-A in CML patients who are sensitive to IFN-A alone but fail to achieve a major cytogenetic response may be beneficial in some patients and should be further investigated.",
keywords = "Chronic myelogenous leukemia, Cytogenetic response, GM-CSF, Interferon-alfa",
author = "J. Cortes and H. Kantarjian and S. O'Brien and R. Kurzrock and M. Keating and M. Talpaz",
year = "1998",
month = "1",
day = "1",
doi = "10.1038/sj.leu.2401033",
language = "English (US)",
volume = "12",
pages = "860--864",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia

AU - Cortes, J.

AU - Kantarjian, H.

AU - O'Brien, S.

AU - Kurzrock, R.

AU - Keating, M.

AU - Talpaz, M.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Patients with chronic myelogenous leukemia (CML) who achieve a major cytogenetic remission when treated with interferon-α (IFN-A) have a survival advantage when compared to patients with no cytogenetic response. We investigated the effect of combining granulocyte-macrophage colony-stimulating factor (GM-CSF) with IFN-A in the cytogenetic response of patients with minor responses to IFN-A alone. CML patients were eligible if they had shown sensitivity to IFN-A as determined by achievement of a hematologic or cytogenetic response, but failed to achieve or lost a major cytogenetic response after a minimum of 12 months of therapy with IFN-A alone. Patients received GM-CSF 30 μg/m2 daily, subcutaneously and the dose was escalated to 60 μg/m2 if tolerated. IFN-A was continued at the same dose being received by the patient and escalated when possible. Fourteen evaluable patients were included, 13 in chronic phase and one in accelerated phase. The best response prior to GM-CSF was a transient major cytogenetic response in two patients (14%), minor cytogenetic response in nine (64%), and complete hematologic response in three (22%). The median time on IFN-A prior to the start of GM-CSF was 39 months (range 12-72 months). Four patients achieved a significant cytogenetic response, including two complete (14%) and two partial (14%) cytogenetic remissions during therapy. One partial cytogenetic remission converted to complete shortly after therapy was discontinued. Two other patients had a significant reduction in the percentage of Philadelphia chromosome-positive metaphases. The dose of IFN-A could be escalated in half of the patients treated. No toxicity could be attributed to the addition of GM-CSF. We conclude that the addition of GM-CSF to the treatment with IFN-A in CML patients who are sensitive to IFN-A alone but fail to achieve a major cytogenetic response may be beneficial in some patients and should be further investigated.

AB - Patients with chronic myelogenous leukemia (CML) who achieve a major cytogenetic remission when treated with interferon-α (IFN-A) have a survival advantage when compared to patients with no cytogenetic response. We investigated the effect of combining granulocyte-macrophage colony-stimulating factor (GM-CSF) with IFN-A in the cytogenetic response of patients with minor responses to IFN-A alone. CML patients were eligible if they had shown sensitivity to IFN-A as determined by achievement of a hematologic or cytogenetic response, but failed to achieve or lost a major cytogenetic response after a minimum of 12 months of therapy with IFN-A alone. Patients received GM-CSF 30 μg/m2 daily, subcutaneously and the dose was escalated to 60 μg/m2 if tolerated. IFN-A was continued at the same dose being received by the patient and escalated when possible. Fourteen evaluable patients were included, 13 in chronic phase and one in accelerated phase. The best response prior to GM-CSF was a transient major cytogenetic response in two patients (14%), minor cytogenetic response in nine (64%), and complete hematologic response in three (22%). The median time on IFN-A prior to the start of GM-CSF was 39 months (range 12-72 months). Four patients achieved a significant cytogenetic response, including two complete (14%) and two partial (14%) cytogenetic remissions during therapy. One partial cytogenetic remission converted to complete shortly after therapy was discontinued. Two other patients had a significant reduction in the percentage of Philadelphia chromosome-positive metaphases. The dose of IFN-A could be escalated in half of the patients treated. No toxicity could be attributed to the addition of GM-CSF. We conclude that the addition of GM-CSF to the treatment with IFN-A in CML patients who are sensitive to IFN-A alone but fail to achieve a major cytogenetic response may be beneficial in some patients and should be further investigated.

KW - Chronic myelogenous leukemia

KW - Cytogenetic response

KW - GM-CSF

KW - Interferon-alfa

UR - http://www.scopus.com/inward/record.url?scp=0031833734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031833734&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2401033

DO - 10.1038/sj.leu.2401033

M3 - Article

C2 - 9639411

AN - SCOPUS:0031833734

VL - 12

SP - 860

EP - 864

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -